BioArctic AB is a pharmaceutical company based in Sweden. With a high ESG risk rating score of 32.3, the company specializes in researching disease-modifying treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS. BioArctic is also developing a treatment for complete spinal cord injury using a combination of a biodegradable medical device and a drug substance. The company generates most of its revenue from Asia.